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Immunostimulation in the Urinary Bladder by Local Application of Nocardia
rubra Cell-Wall Skeletons (Rubratin) and Bacillus Calmette-Guérin as Therapy
for Superficial Bladder Cancer: A Comparative Study
Elizabeth C. de Boer, Theo M. De Reijke,
Pieter C. N. Vos, Karl-Heinz Kurth,
and Denis H. J. Schamhart
Department of Urology, University of Amsterdam,
The Netherlands
Twelve patients with superficial bladder cancer were treated with intravesical instillations
of Rubratin (ASTA Pharma AG, Frankfurt, Germany), a cell-wall preparation of Nocardia
rubra. The objective was to compare the immunostimulating effect of Rubratin with that of
bacillus Calmette-Guérin (BCG). Local immunostimulation was determined by cytokine in-
duction in serially collected urine samples during the first 24 h after each instillation, leukocyte
influx into the urine, and phenotypic analysis of the lymphocyte fraction. Levels of Rubratin-
induced interleukin (IL)-1b, IL-6, and tumor necrosis factor–a were significantly elevated
compared with pretherapy levels. Rubratin induced leukocyte influx into the urine. T-cell
activation (IL-2 receptor and human leukocyte antigen–DR expression) can be induced, and
CD4:CD8 cell ratios can be increased. All parameters indicated that Rubratin-induced im-
munostimulation was less than that associated with BCG. In conclusion, although local Rub-
ratin-induced immunostimulation occurs in a limited number of patients, the amount of
immunocompetent cells attracted to the bladder seems to be less than that associated with
BCG therapy, thus resulting in lower levels of cytokine production (which may reflect less
clinical efficacy).
Recurrent superficial bladder cancer provides unique possi-
bilities to investigate the immunotherapeutic potential of new
agents. We studied the immunostimulating and immunother-
apeutic potential of a commercially available cell-wall skeleton
preparation of Nocardia rubra (Rubratin, ASTA Pharma AG,
Frankfurt, Germany), which is a bacterial species taxonomi-
cally related to BCG. Intravesical immunotherapy with the bi-
ological response modifier BCG is an effective treatment for
carcinoma in situ (Tis) and superficial (Ta, T1) papillary tran-
sitional-cell carcinoma of the urinary bladder [1, 2]. Most pa-
tients tolerate local BCG treatment well, and complications are
usually minor; however, serious and even fatal reactions re-
sulting from systemic infection with the viable microorganism
can occur [3], indicating a need for new therapeutics.
The immunostimulating and immunotherapeutic activity of
Rubratin has been reported in a number of experimental tumors
in mice, rats, and guinea pigs [4–8]. Clinical studies from Japan
and Germany have confirmed these experimental results [7, 9,
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10]. In prospective, randomized, phase III trials, a benefit of
Rubratin, with respect to remission or survival time, was shown
for a variety of nonurologic tumors of different origin [11–16].
Rubratin was also used in monotherapy, in adjuvant therapy,
and in combination with chemotherapy for patients with lung,
colorectal, and gastric carcinoma, malignant glioma, and acute
leukemia. In these studies, the preparation was given intrad-
ermally and by the intratumoral and intrapleural route. How-
ever, nothing is known regarding the immunotherapeutic ac-
tivity of Rubratin if it is applied intravesically in superficial
bladder cancer.
In this study, patients with superficial bladder cancer (pTa,
pT1) were treated intravesically with Rubratin, according to a
treatment schedule generally used for BCG. The objective was
to compare the immunostimulating activity of Rubratin with
that of BCG, with regard to the potential use of Rubratin in
the treatment of superficial bladder carcinoma. Local immu-
nostimulation was determined by measurement of cytokine (IL-
1b, IL-2, IL-6, and TNF-a) induction in the urine and leukocyte
influx into the urine and by phenotypic analysis of the lym-
phocyte fraction of these leukocytes, as described elsewhere
[17–19] for BCG therapy.
Materials and Methods
Patients and treatment protocol. This study included 12 pa-
tients (9 males and 3 females) with primary or recurrent histolog-
ically proven superficial papillary transitional-cell carcinoma of the
urinary bladder (5 patients with TaG1, 6 with TaG2, and 1 with
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T1G2; all were designated as having “low risk” for progression,
according to the criteria of Kurth et al. [20]). Patients with carci-
noma in situ (TisG3) were excluded. To study the immunologic
effect as well as the antitumor efficacy of Rubratin, a marker lesion
(0.5–1 cm) was left in the bladder after transurethral resection of
all other visible tumors in the initial 4 patients. These 4 patients
were treated with 6 weekly intravesical instillations of Rubratin
(dose, 1.5 mg). Because no response by the marker lesion was
observed in these patients, the other 8 patients were treated pro-
phylactically according to a revised protocol; in these patients, all
visible tumors were resected by transurethral resection. In these 8
patients, the immunologic effect of 6 weekly intravesical instilla-
tions of Rubratin (dose for 5 patients, 3.0 mg/week; dose for 3
patients, 4.5 mg/week) was studied, and they were followed up for
recurrence of disease by 3 monthly examinations with cystoscopy
and cytological analysis. Patients were monitored for local (cystitis
and hematuria) and systemic (fever and allergic reactions) adverse
events.
A group of 11 consecutive patients who had superficial transi-
tional-cell carcinoma and were treated, within the same period,
with 6 weekly intravesical instillations of BCG (∼5 cfu8–10 3 10
or 27 mg of dry weight; Connaught Laboratories, North York,
Ontario, Canada) were control subjects for comparison of immuno-
stimulation.
Rubratin. Rubratin is a lyophylisate that, on reconstitution,
forms an injectable oil-in-water emulsion [8]. The contents of an
injection vial (0.5 mg) were reconstituted in 1 mL of 0.9% saline.
For intravesical instillation, the required number of vials for the
1.5-, 3.0-, or 4.5-mg dose was diluted to an end volume of 50 mL
in saline.
Determination of cytokines in urine. Urine samples (obtained
during spontaneous voiding) were collected before instillation and
at 2–4, 4–6, 6–12, and 12–24 h thereafter during each of the 6
instillations. Samples were immediately frozen to 2207C. After-
ward, specimens were thawed, centrifuged (300g) to remove cells
and debris, and stored in aliquots at 2207C until analysis. Levels
of IL-1b, IL-2, IL-6, and TNF-a in urine were determined, as
reported elsewhere [19], with the use of commercially available,
highly specific, reproducible ELISAs using an oligoclonal system
(Medgenix, Fleurus, Belgium). By use of this method, baseline
urinary cytokine levels ( pg of IL-1b/mmol creatinine,3.7 5 6.2
U of IL-2/mmol creatinine, pg of IL-6/mmol0.0 5 0.1 5.9 5 12.8
creatinine, and pg of TNF-a/mmol creatinine) were es-0.2 5 0.8
tablished in 134 preinstillation samples from 25 patients with su-
perficial bladder cancer. Data on cytokines were standardized to
urinary creatinine levels to correct for hydration in voided urine.
Fluorescence-activated cell sorter (FACS) analysis of lymphocytes
from urine. In fresh urine samples obtained 2–4 h after the first,
third, and sixth instillations, the total number of viable leukocytes
was determined using the trypan blue exclusion. Leukocytes were
washed (centrifugation for 5 min at 300g) twice in PBS (pH 7.2)
with 0.2% albumin (Boehringer Mannheim, Mannheim, Germany),
0.02% K-EDTA (Merck, Darmstadt, Germany), and 0.01% NaN3
(Merck). Cells ( ) were labeled with 100 mL of monoclonal55 3 10
antibody (mAb) in PBS with the described additions. CD45 mAb
to leukocytes (1:10), CD3 mAb to T cells (1:10), CD4 mAb to Th/
i (1:10), CD8 mAb to Ts/c (1:10), CD25 mAb to IL-2 receptor (1:
10), CD14 mAb to monocytes/macrophages (1:10), CD66 mAb
granulocytes (1:500), and mAb to human leukocyte antigen–DR
(HLA-DR; 1:500) were obtained from the Central Laboratory of
the Netherlands Red Cross Blood Transfusion Service (Amster-
dam), and CD20 mAb to B cells (1:5) and CD56 mAb to natural
killer/Tc cells (1:10) were from Becton Dickinson (BD Biosciences,
Woerden, Netherlands). A fluorescein-conjugated F(ab′)2 fragment
from rabbit antibody to mouse Ig (Dako, Glostrup, Denmark) was
used as a second antibody (100 mL; 1:40 dilution in PBS with the
described additions). Labeled cells were fixed in 300 mL of 0.5%
paraformaldehyde in PBS. FACS analysis (FACScan, BD Biosci-
ences, Woerden, Netherlands) was performed the following day, as
described elsewhere [18].
Statistical methods. Differences between Rubratin- or BCG-
treated patients and control subjects were analyzed using the 2-
tailed Wilcoxon’s rank-sum test for the unpaired case.
Results
Cytokines in urine. In serial urine samples obtained during
the first 24 h after each of the 6 weekly instillations of Rubratin,
all cytokines (i.e., IL-1b, IL-2, IL-6, and TNF-a) could be de-
tected. The highest cytokine concentrations were generally ob-
served in urine samples obtained 2–4 h or 4–6 h after instillation,
in accordance with cytokine induction by BCG [18]. No differ-
ences between the 1.5-, 3.0-, and 4.5-mg doses of Rubratin were
observed with regard to the levels of cytokine induction (results
not shown); therefore, the data were combined. In figure 1, cy-
tokine levels during the 6 weeks of intravesical treatment with
Rubratin are presented in comparison with those seen during
BCG therapy. Pretherapy cytokine levels were not different for
the Rubratin- and BCG-treated patients ( ). For IL-1bP p .621
(figure 1A), an increase over the pretherapy level was already
observed after the first instillation of Rubratin ( ); thisP p .025
level increased moderately up to the sixth instillation of Rubratin
( ). No significant differences in levels of Rubratin- andP p .015
BCG-induced IL-1b (week 6, ) were seen, althoughP p .442
maximum urinary IL-1b concentrations were higher (see upper
range) during BCG treatment.
For urinary levels of Rubratin-induced IL-2 (figure 1B), a
trend for an increase over the pretherapy level was found (low-
est level [ ] at week 4; highest level [ ] at weekP p .070 P p .162
2). In contrast, IL-2 levels clearly increased during a 6-week
treatment course with BCG: at week 6, significantly lower
amounts of IL-2 were induced by Rubratin compared with
BCG ( ). For IL-6 (figure 1C), Rubratin-induced levelsP p .002
were higher than pretherapy levels after the first instillation
( ); however, these levels declined thereafter to a non-P p .002
significant difference at week 6 ( ). At week 6, the dif-P p .926
ference between BCG- and Rubratin-induced amounts of
IL-6 was highly significant ( ). Urinary levels of Rub-P p .0001
ratin-induced TNF-a (figure 1D) were significantly increased
at week 3 only ( ), compared with pretherapy levels.P p .017
At weeks 5 and 6, levels of Rubratin-induced TNF-a were lower
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Figure 1. Urinary levels of IL-1b (A), IL-2 (B), IL-6 (C), and TNF-a (D) during a 6-week course of intravesical therapy with Rubratin (ASTA
Pharma AG, Frankfurt, Germany) or BCG for superficial bladder cancer. Urine samples were collected before therapy (week 0) and serially
during the first 24 h after each of 6 weekly instillations (weeks 1–6). For individual patients, the highest cytokine concentration observed after
each week was evaluated. White boxes denote cytokine concentrations in 12 Rubratin-treated patients; shaded diagonally striped boxes, cytokine
concentrations in 11 BCG-treated patients. The lower and upper quartiles are indicated by the corresponding vertical ends of the box. The median
value is indicated by the central horizontal line in the box. Median values are connected by an unbroken line for Rubratin and by a broken line
for BCG. Minimum and maximum cytokine concentrations (range) are indicated by the T bars
than levels of BCG-induced TNF-a ( and ,P p .017 P p .022
respectively).
Leukocyte counts in urine. Leukocyte counts were deter-
mined for 8 patients treated with the highest 2 doses of Rub-
ratin. Rubratin was found to induce leukocyte influx into the
urine after intravesical instillation: for all samples investigated
(which were obtained 2–4 h after the first, third, and sixth
instillations), the leukocyte count after instillation was higher
than that noted before instillation. No differences were ob-
served between the 3.0- and 4.5-mg doses of Rubratin, with
regard to the numbers of induced leukocytes (results not
shown); therefore, the data were combined. In figure 2, the
leukocyte counts in urine samples obtained from 8 patients
during 6 weeks of intravesical treatment with Rubratin are com-
pared with those in urine samples from 8 BCG-treated patients.
Pretherapy leukocyte counts were not different for the Rub-
ratin- and BCG-treated patients ( ). After weeks 1, 3,P p .518
and 6, counts of Rubratin-induced leukocytes in urine samples
obtained 2–4 h after instillation were greater than pretherapy
counts ( , , and , respectively). Uri-P p .027 P p .002 P p .006
nary leukocyte counts after Rubratin therapy increased from
the first to the third instillation but not from the third to the
sixth instillation. This finding was clearly in contrast to that
for BCG therapy, in which a gradual elevation was seen during
the 6-week treatment course. Leukocyte counts in urine samples
were significantly lower after the sixth instillation of Rubratin
than after that of BCG ( ).P p .005
FACS analysis of leukocytes. FACS analysis was performed
on leukocytes in urine samples obtained 2–4 h after the first,
third, and sixth instillations in 7 patients treated with the 2
highest doses of Rubratin (3.0 and 4.5 mg). Small percentage
of monocytes/macrophages ( ) and lymphocytes3.3 5 2.1%
( ) were detectable in addition to most granulocytes,0.4 5 0.3%
which is similar to the situation after BCG instillation [18]. No
differences within these percentages were observed for the 2
different doses of Rubratin; therefore, the data were combined.
Because the composition of the lymphocyte population in urine
after BCG therapy seems to be representative of the BCG-
induced chronic lymphocytic infiltrate in the bladder wall, the
phenotype of urinary lymphocytes after Rubratin instillations
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Figure 2. Leukocyte counts in urine during a 6-week course of in-
travesical therapy with Rubratin (ASTA Pharma AG, Frankfurt, Ger-
many) or BCG for superficial bladder cancer. Urine samples were ob-
tained before therapy (week 0) and 2–4 h after the first, third, and sixth
instillations. White boxes denote leukocyte counts in 8 Rubratin-
treated patients; shaded diagonally striped boxes, leukocyte counts in
8 BCG-treated patients. Lower and upper quartiles are indicated by
the corresponding vertical ends of the box. The median value is in-
dicated by the central horizontal line in the box. Median values are
connected by an unbroken line for Rubratin and by a broken line for
BCG. Minimum and maximum numbers of leukocytes (range) are in-
dicated by the T bars.
was determined. Because of the small number of lymphocytes,
accurate FACS analysis was not possible after the first instil-
lation. After the sixth instillation, analysis was possible for 5
of the 7 patients: cells in the lymphocyte gate consisted mostly
of CD31 T cells ( ), with lower percentages of CD20159 5 17%
B cells ( ) and small percentages of CD561 natural14 5 20%
killer/Tc cells ( ). For 2 of these 5 patients, relatively high2 5 3%
percentages of lymphocytes expressing IL-2 receptors (CD251)
and HLA-DR were observed, indicating T-cell activation. For
the same 2 patients, an increased CD4:CD8 cell ratio was
found. In figure 3, these data are shown in comparison with
levels of IL-2 receptor ( ) and HLA-DR ( )P p .143 P p .222
expression and CD4:CD8 cell ratios ( ) after 6 BCGP p .256
instillations and suggests a trend for a lower level of T-cell
activation and a lower CD4:CD8 cell ratio after Rubratin treat-
ment than after BCG therapy.
Tumor response. A response was not observed in the
marker lesions (at week 10) in 4 Rubratin-treated patients. Of
the additional 8 Rubratin-treated patients who received pro-
phylaxis, 4 had early recurrence of disease (mean time to re-
currence, 3.8 months). For the 4 patients without recurrence,
the mean time of follow-up was 10.5 months.
Discussion
This study assessing the immunostimulating capacity of in-
travesically applied Rubratin provided a unique opportunity
for comparison with the level of immunostimulation induced
by intravesical treatment with BCG; both Rubratin and BCG
are similar types of biological response modifiers (i.e., bacterial
preparations). It is shown that local immunostimulation can
be accomplished by intravesical application of the N. rubra cell-
wall skeleton preparation Rubratin. Significantly elevated
amounts of IL-1b, IL-6, TNF-a, and leukocytes were observed
in urine samples, whereas a trend for an increase was found
for IL-2. FACS analysis of lymphocytes obtained from urine
samples suggested that T-cell activation may be induced (IL-2
receptor and HLA-DR expression) and CD4:CD8 cell ratios
can be increased after Rubratin treatment. However, immu-
nostimulation by Rubratin was considerably less than that by
BCG, which is the classical biological response modifier used
as treatment of carcinoma in situ (Tis) and prophylaxis for
superficial (Ta/T1) bladder tumors.
Our observations of local immunostimulation resulting from
intravesically applied Rubratin agree with the findings of Jur-
incic et al. [21], who reported an increased number of macro-
phages, monocytes, granulocytes, and CD41 T cells in mucosa
and submucosa of the bladder; these findings were determined
by immunohistochemical analysis. With regard to urinary cy-
tokine induction by Rubratin, Jurincic et al. [21] studied only
IL-1b. They found an increase in the IL-1b level, which was
also observed in this study.
A major cause of the reduced immunostimulating capacity
of Rubratin compared with BCG may be that the BCG prep-
aration contains viable bacteria, whereas Rubratin contains
bacterial cell walls only. For BCG, viability of the preparation
is probably important for therapeutic efficacy [22], and alter-
native immunomodulators have not yet shown comparable an-
titumor efficacy [3, 23–25]. Experimental data obtained from
the guinea pig model described by Van der Meijden et al. [26]
suggested the need for viable organisms: heat-killed BCG had
less immunostimulating capacity than did viable BCG when
applied intravesically (unpublished data, E. C. de Boer). In
agreement with these observations, assuming that the BCG-
associated immune reaction is required for antitumor efficacy,
Kelley et al. [22] reported on the importance of the viability of
the BCG preparation for clinical efficacy against superficial
bladder cancer. The low level of immunostimulation observed
in the present study after intravesical instillations of Rubratin
may be comparable. However, Chin et al. [27] recently reported
experimental results indicating that a mycobacterial cell-wall
preparation obtained from Mycobacterium phlei invokes an in-
flammatory response in the mouse similar to that of a live BCG
organism and retains antitumor action.
Regarding the intravesical administration of bacteria other
than BCG, it is not clear whether the type of bacterial species
(either viable or nonviable) is an influence on the level of im-
munostimulation. Bacteria commonly associated with urinary
tract infections can induce elevated levels of urinary cytokines
[28], although the levels are not as high as those associated with
BCG [29]. In addition to being produced by infiltrating cells
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Figure 3. Flow cytofluorometric analysis of IL-2 receptor (IL-2R) and histocompatibility complex class II (human leukocyte antigen–DR
[HLA-DR]) expression and CD4:CD8 cell ratios in lymphocytes in urine samples obtained 2–4 h after 6 instillations of Rubratin (ASTA Pharma
AG, Frankfurt, Germany) or BCG as therapy for superficial bladder cancer. Data for individual patients (5 Rubratin-treated patients and 7
BCG-treated patients) are shown. Unbroken lines represent median values.
of the immune system, urothelial cells may be a source of uri-
nary cytokines such as IL-1b, IL-6, and TNF-a [30, 31]. Re-
cently, it was reported by our group that interaction of uro-
thelial cells with BCG resulted in enhanced secretion of IL-6
and TNF-a by the urothelial cells, which was 110-fold higher
than that with Rubratin or other whole, viable, urinary tract
infection–inducing bacteria [32].
The data agree with results obtained in this study and are
thus suggestive of a role for this phenomenon within local im-
munostimulation following bladder instillation.
Although there is increasing evidence regarding the impor-
tance of local T-cell infiltration and immune activation for ef-
ficacy [33–36], the exact mode of action of BCG as an antitumor
modality in bladder cancer is not known, and a firm link be-
tween an immune-mediated mode of action and a clinical (tu-
mor) response is still lacking. Our recent results from investi-
gations of induction of urinary cytokines by means of
intravesical therapy with BCG indicate an association between
absence of cytokine induction and early recurrence of disease
[37]. In agreement with these observations, the low levels of
Rubratin-induced cytokines in this study seem to be associated
with the absence of appreciable antitumor efficacy of intraves-
ical instillations of Rubratin, although no firm conclusions re-
garding the antitumor efficacy of Rubratin can be drawn from
this study because of the small number of patients.
Intravesical BCG treatment for superficial bladder cancer is
well tolerated by 195% of patients, although serious compli-
cations, such as systemic BCG sepsis, can occur. The most
frequently encountered side effect of the treatment is local blad-
der irritation (which occurs in 190% of patients); this adverse
effect usually persists for ∼2 days and begins after repeated
instillations. It is probably a result of locally induced inflam-
matory and immunologic processes. That no local or systemic
side effects were observed in the patients treated with Rubratin
in the present study is in agreement with the limited immu-
nologic effects reported here.
The results of phenotypic analysis for a limited number of
Rubratin-treated patients suggested that T-cell activation was
induced in some (2 of 5) patients. However, in contrast with
observations for BCG-treated patients [38], no correlation be-
tween phenotypic T-cell activation and the amount of urinary
cytokines was observed for the Rubratin-treated patients. This
finding may be explained by the considerably lower amount of
urinary leukocytes induced by Rubratin compared with BCG
(figure 2). In conclusion, although local immunostimulation by
intravesical administration of Rubratin may be induced in a
limited number of patients, the amount of immunocompetent
cells attracted to the bladder is probably not as high as that
seen with intravesical treatment with BCG, resulting in lower
amounts of cytokine production (which may be reflected in less
clinical efficacy). Further study using intravesical instillation of
Rubratin (even with doses of 14.5 mg) in superficial transitional
cell carcinoma of the bladder is limited because of the presented
immunologic data, clinical data, and cost-effectiveness of this
treatment. For future studies with similar immune modulators,
cytokine induction may be used in addition to clinical evalu-
ation in the testing of new agents for treatment of superficial
bladder cancer.
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carcinoma in situ of the bladder. J Urol 1986;135:265–7.
2. Lamm DL, Griffith G, Pettit LL, Nseyo UO. Current perspectives and treat-
ment of superficial bladder cancer. Urology 1992;39:301–8.
3. Lamm DL, Van der Meijden APM, Morales A, et al. Incidence and treatment
of complications of bacillus Calmette-Guérin intravesical therapy in su-
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